257 related articles for article (PubMed ID: 29158144)
21. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
Sucher AJ; Chahine EB; Cogan P; Fete M
Ann Pharmacother; 2015 Sep; 49(9):1046-56. PubMed ID: 26160970
[TBL] [Abstract][Full Text] [Related]
22. Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections.
Castón JJ; De la Torre Á; Ruiz-Camps I; Sorlí ML; Torres V; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956431
[TBL] [Abstract][Full Text] [Related]
23. Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections.
Escolà-Vergé L; Pigrau C; Los-Arcos I; Arévalo Á; Viñado B; Campany D; Larrosa N; Nuvials X; Ferrer R; Len O; Almirante B
Infection; 2018 Aug; 46(4):461-468. PubMed ID: 29594953
[TBL] [Abstract][Full Text] [Related]
24. Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant.
Peghin M; Maiani M; Castaldo N; Givone F; Righi E; Lechiancole A; Sartor A; Pea F; Livi U; Bassetti M
Infection; 2018 Apr; 46(2):263-265. PubMed ID: 29086895
[TBL] [Abstract][Full Text] [Related]
25. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
Gentile I; Maraolo AE; Borgia G
Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
[No Abstract] [Full Text] [Related]
26. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Cho JC; Fiorenza MA; Estrada SJ
Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
[TBL] [Abstract][Full Text] [Related]
27. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
Bassetti M; Castaldo N; Cattelan A; Mussini C; Righi E; Tascini C; Menichetti F; Mastroianni CM; Tumbarello M; Grossi P; Artioli S; Carannante N; Cipriani L; Coletto D; Russo A; Digaetano M; Losito AR; Peghin M; Capone A; Nicolè S; Vena A;
Int J Antimicrob Agents; 2019 Apr; 53(4):408-415. PubMed ID: 30415002
[TBL] [Abstract][Full Text] [Related]
28. Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.
Gelfand MS; Cleveland KO
Clin Infect Dis; 2015 Sep; 61(5):853-5. PubMed ID: 26021991
[No Abstract] [Full Text] [Related]
29. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
[TBL] [Abstract][Full Text] [Related]
30. Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.
Munita JM; Aitken SL; Miller WR; Perez F; Rosa R; Shimose LA; Lichtenberger PN; Abbo LM; Jain R; Nigo M; Wanger A; Araos R; Tran TT; Adachi J; Rakita R; Shelburne S; Bonomo RA; Arias CA
Clin Infect Dis; 2017 Jul; 65(1):158-161. PubMed ID: 28329350
[TBL] [Abstract][Full Text] [Related]
31. Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients.
Finklea JD; Hollaway R; Lowe K; Lee F; Le J; Jain R
Diagn Microbiol Infect Dis; 2018 Sep; 92(1):75-77. PubMed ID: 29884565
[TBL] [Abstract][Full Text] [Related]
32. Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa.
Xipell M; Paredes S; Fresco L; Bodro M; Marco F; Martínez JA; Soriano A
J Glob Antimicrob Resist; 2018 Jun; 13():165-170. PubMed ID: 29366723
[TBL] [Abstract][Full Text] [Related]
33. Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.
Maraolo AE; Cascella M; Corcione S; Cuomo A; Nappa S; Borgia G; De Rosa FG; Gentile I
Expert Rev Anti Infect Ther; 2017 Sep; 15(9):861-871. PubMed ID: 28803496
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
[TBL] [Abstract][Full Text] [Related]
35. Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.
Kuti JL; Ghazi IM; Quintiliani R; Shore E; Nicolau DP
Int J Antimicrob Agents; 2016 Sep; 48(3):342-3. PubMed ID: 27451086
[No Abstract] [Full Text] [Related]
36. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
Seifert H; Körber-Irrgang B; Kresken M;
Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
[TBL] [Abstract][Full Text] [Related]
37. Ceftolozane-tazobactam for the treatment of ventilator-associated infections by colistin-resistant Pseudomonas aeruginosa.
Álvarez Lerma F; Muñoz Bermudez R; Grau S; Gracia Arnillas MP; Sorli L; Recasens L; Mico García M
Rev Esp Quimioter; 2017 Jun; 30(3):224-228. PubMed ID: 28361526
[TBL] [Abstract][Full Text] [Related]
38. Use of continuous-infusion ceftolozane/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature.
Sheffield M; Nelson D; O'Neal M; Gould AP; Bouchard J; Nicolau D; Justo JA; Hucks J; Bookstaver PB
Int J Antimicrob Agents; 2020 Nov; 56(5):106158. PubMed ID: 32919007
[TBL] [Abstract][Full Text] [Related]
39. ESBL E coli and P. aeruginosa Resistance to Ceftolozane-Tazobactam in a Patient with a Liver Abscess. The Search for an Omnipotent Antibiotic Goes On!
Teleb M; Soto-Ruiz E; Dominguez DC; Antony S
Infect Disord Drug Targets; 2018; 18(1):81-85. PubMed ID: 27411471
[TBL] [Abstract][Full Text] [Related]
40. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
Natesan S; Pai MP; Lodise TP
J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]